Monoclonal antibody 14C5 targets integrin αvβ 5

Molecular Cancer Therapeutics

Volumn 7, Issue 12, 2008, Pages 3771-3779

  Burvenich, Ingrid ^a   Schoonooghe, Steve ^a   Vervoort, Liesbet ^a   Dumolyn, Caroline ^a   Coene, Elisabeth ^a   Vanwalleghem, Lieve ^a   Van Huysse, Jacques ^a   Praet, Marleen ^a   Cuvelier, Claude ^a   Mertens, Nico ^a   De Vos, Filip ^a,b   Slegers, Guido ^a  

^a GHENT UNIVERSITY   (Belgium)

^b Multimedia Lab   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTEGRIN; ALPHA2 INTEGRIN; ALPHA3 INTEGRIN; ALPHAVBETA5 INTEGRIN; BETA1 INTEGRIN; BETA2 INTEGRIN; BETA3 INTEGRIN; BETA4 INTEGRIN; CD51 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 14C5; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR;

ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; DRUG PROTEIN BINDING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; STAINING; TUMOR CELL;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; COLONIC NEOPLASMS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; PROTEIN BINDING; RECEPTORS, VITRONECTIN; TISSUE DISTRIBUTION;

EID: 57749117781     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0600     Document Type: Article

References (41)

1. De Potter CR, Schelfhout AM, De Smet FH, et al. A monoclonal antibody directed against a human cell membrane antigen prevents cell substrate adhesion and tumor invasion. Am J Pathol 1994;144:95-103.
2. Coene E, Schelfhout AM, De Ridder L, De Potter CR. Generation of a monoclonal antibody directed against a human cell substrate adhesion molecule and the expression of the antigen in human tissues. Hybridoma 1997;16:77-83.
3. Giffels P, Kohler S, De Potter C, et al. MAb 14C5 against a human cell substrate adhesion molecule for inhibition of tumor growth in vivo. Eur J Cancer 1997;33:41-2.
4. Wagner U, Kohler S, Prietl G, et al. Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5). Zentralbl Gynakol 1999;121:190-5.
5. Lahorte CM, Bacher K, Burvenich I, et al. Radiolabeling, biodistribution, and dosimetry of (123)I-mAb 14C5: a new mAb for radioimmunodetection of tumor growth and metastasis in vivo. J Nucl Med 2004;45:1065-73.
6. Burvenich I, Schoonooghe S, Cornelissen B, et al. In vitro and in vivo targeting properties of iodine-123- or iodine-131-labeled monoclonal antibody 14C5 in a non-small cell lung cancer and colon carcinoma model. Clin Cancer Res 2005;11:7288-96.
7. Burvenich IJ, Schoonooghe S, Blanckaert P, et al. Biodistribution and planar gamma camera imaging of (123)I- and (131)I-labeled F(ab′)(2) and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor. Nucl Med Biol 2007;34:257-65.
8. Reinholt FP, Hultenby K, Oldberg A, Heinegard D. Osteopontin - a possible anchor of osteoclasts to bone. Proc Natl Acad Sci U S A 1990;87:4473-5.
9. 3 integrin stimulates immediate cell signals in osteoclasts. J Biol Chem 1991;266:20369-74.
10. Willems A, Leoen J, Schoonooghe S, Grooten J, Mertens N. Optimizing expression and purification from cell culture medium of trispecific recombinant antibody derivatives. J Chromatogr B Analyt Technol Biomed Life Sci 2003;786:161-76.
11. Mizejewski GJ. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 1999;222:124-38.
12. Wehrle-Haller B, Imhof BA. Integrin-dependent pathologies. J Pathol 2003;200:481-7.
13. Imhof BA, Vadas MA. New therapeutic targets in vascular biology. Thromb Haemost 2003;90:557-9.
14. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 2004;90:561-5.
15. Ruegg C, Dormond O, Mariotti A. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis. Biochim Biophys Acta 2004;1654:51-67.
16. 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J Cell Biol 1992;117:1101-7.
17. Kerr JS, Slee AM, Mousa SA. The α v integrin antagonists as novel anticancer agents: an update. Expert Opin Investig Drugs 2002;11:1765-74.
18. 5 integrins in growth and metastasis of murine mammarycarcinomas. Cancer Res 2005;65:10324-9.
19. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct α v integrins. Science 1995;270:1500-2.
20. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med 2002;8:918-21.
21. v integrins. Int J Cancer 2000;87:716-23.
22. 5- integrins mediate early steps of metastasis formation. Eur J Cancer 2005;41:1065-72.
23. Dechantsreiter MA, Planker E, Matha B, et al. N-methylated cyclic RGD peptides as highly active and selective α(V)β(3) integrin antagonists. J Med Chem 1999;42:3033-40.
24. Li LS, Rader C, Matsushita M, et al. Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devices. J Med Chem 2004;47:5630-40.
25. 3 antagonists as novel anticancer agents. J Med Chem 2006;49:4526-34.
26. 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide. Int J Cancer 2007;120:605-10.
27. 5 in patients with advanced solid tumours. Eur J Cancer 2003;39:917-26.
28. Davis H, Prabhakar U, Jang H. A rational approach for a phase I clinical study design to evaluate CNTO 95, a novel, fully human anti-a(v) monoclonal antibody (MAb), in patients with solid tumors. J Clin Oncol 2004;22:190S.
29. v integrins, in patients with solid tumors. J Clin Oncol 2004;22:224S.
30. Trikha M, Zhou Z, Nemeth JA, et al. CNTO 95, a fullyhuman monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 2004;110:326-35.
31. v integrin monoclonal antibody, despite widespread tissue binding. Clin Cancer Res 2005;11:6959-65.
32. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64.
33. 3. Clin Cancer Res 2000;6:3056-61.
34. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Cilengitide targeting of α(v)β(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002;62:4263-72.
35. Lewis MR. Radiolabeled RGD peptides move beyond cancer: PET imaging of delayed-type hypersensitivity reaction. J Nucl Med 2005;46:2-4.
36. Dijkgraaf I, Kruijtzer JA, Liu S, et al. Improved targeting of the α(v)β(3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging 2007;34:267-73.
37. 3-integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging 2006;33 Suppl 1:54-63.
38. 3 expression with 18F-FRGD2. J Nucl Med 2006;47:113-21.
39. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392-401.
40. Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A 1990;87:7235-9.
41. Scott AM, Wiseman G, Welt S, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 2003;9:1639-47.